Innate Pharma (IPHA) Scheduled to Post Quarterly Earnings on Thursday

Innate Pharma (NASDAQ:IPHAGet Free Report) will release its earnings data before the market opens on Thursday, March 21st. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Innate Pharma Trading Up 1.7 %

Shares of Innate Pharma stock opened at $2.43 on Wednesday. Innate Pharma has a 52-week low of $1.81 and a 52-week high of $3.57. The company’s 50-day simple moving average is $2.61 and its 200-day simple moving average is $2.59.

Institutional Investors Weigh In On Innate Pharma

Several large investors have recently made changes to their positions in the company. Balyasny Asset Management LLC bought a new position in Innate Pharma during the 3rd quarter worth approximately $32,000. Citadel Advisors LLC purchased a new stake in shares of Innate Pharma during the second quarter worth $42,000. Jane Street Group LLC lifted its position in Innate Pharma by 156.3% in the first quarter. Jane Street Group LLC now owns 37,736 shares of the company’s stock valued at $127,000 after purchasing an additional 23,012 shares during the period. Millennium Management LLC lifted its holdings in shares of Innate Pharma by 389.8% during the 4th quarter. Millennium Management LLC now owns 71,684 shares of the company’s stock valued at $267,000 after acquiring an additional 57,050 shares in the last quarter. Finally, BlackRock Inc. lifted its stake in shares of Innate Pharma by 27.4% in the 1st quarter. BlackRock Inc. now owns 504,408 shares of the company’s stock worth $1,695,000 after acquiring an additional 108,335 shares during the period. Institutional investors own 0.29% of the company’s stock.

Innate Pharma Company Profile

(Get Free Report)

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.

Featured Stories

Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.